Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
( MCA-0823) HIV-1 RNA and Integration in HIV-1 Infected Subjects


 Return to List of Clinical Studies
 Return to List of Protocols for HIV and AIDS
HIV-1 RNA Plasma Levels and HIV-1 Integration Sites in HIV-1 Infected Subjects

Principal Investigator:
Marina Caskey M.D.

Investigators:

Contact Information:
Recruitment Specialist
1230 York Avenue
New York, NY 10065
Telephone: 1800RUCARES
Email: rucares@rockefeller.edu
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
The human immunodeficiency virus type 1 (HIV-1) is an infection that attacks the immune system, the system that helps fight bacteria and viruses that we come in contact with. Individuals who have HIV-1 are given medications called antiretroviral medications (medicine that stops HIV-1 from making new particles of itself). In some people, despite taking these medications everyday as prescribed, low levels of HIV particles can still be measured in their blood (viremia). The level of viremia may be so low that the tests that are now commercially available are not sensitive enough to measure these very low levels of HIV particles. Furthermore, the HIV particles that enter the immune cells favor particular places (sites) on the cell. These sites may change once a person starts on antiretroviral medications. Researchers at the Rockefeller University Hospital are doing this study to learn more about the sites on the immune cells that the HIV particle enters both before and after a person starts HIV treatment. Also the researchers want to develop a test to measure the number of HIV particles in the blood to a lower number of copies then is now available in the current standard test. Additionally, the researchers will be evaluating the sensitivity of your HIV to a new class of drugs to potentially treat HIV, called broadly neutralizing antibodies.



Detailed Description of Protocol:




What specifically makes a person eligible for the study?
You may be eligible to enter this study:

1. 18-65 2. HIV positive 3. Do not have Hep B or C

Gender:
Both

Age(s):
18-65

Children permitted to participate:
No

Potential Benefits.....
no benefit



Compensation:
compensation is provided